SCHEMBL2815247

SCHEMBL2815247

Cc1ccc(-c2nc(N)cc(-c3cccc(N4CCOCC4)n3)n2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.44
ADORA1 P30542 6/20 0.44
PIM1 P11309 4/20 0.42
PIM3 Q86V86 3/20 0.42
PIM2 Q9P1W9 3/20 0.42
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MTOR P42345 2/20 0.37
HTT P42858 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
NCF1 P14598 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2810804 0.81 ADORA2A (0.64) ADORA2AADORA1
SCHEMBL2814176 0.78 PIK3CA (0.54) PIM1PIM3PIM2MAPTTSHR
SCHEMBL2814649 0.77 KMT2A (0.49) ADORA2AADORA1PIM1PIM3PIM2
SCHEMBL3978530 0.74 ADORA2A (0.41) ADORA2AADORA1PIM1PIM3PIM2
SCHEMBL3978535 0.74 ADORA2A (0.47) ADORA2AADORA1PIM1PIM3PIM2
SCHEMBL2812966 0.74 ADORA2A (0.69) ADORA2AADORA1MAPTHTTKDM4E
SCHEMBL21495017 0.69 AR (0.50) PIM1PIM3PIM2MAPTMAPK1
SCHEMBL29762448 0.69 GRIN2D (0.53) CRHBPCRHR2MAPTTSHRMAPK1
SCHEMBL246968 0.69 GRIN2D (0.53) CRHBPCRHR2MAPTTSHRMAPK1
SCHEMBL5017768 0.68 ADORA2A (0.46) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
EP-2132197-A2 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall, S.A. (ES) 2009-12-16 EP disclosed
WO-2008116185-A2 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2008-09-25 WO disclosed
WO-2008116185-A2 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA3, ADORA1, ADORA2A ADORA2A 3/4885ADORA1 2/4885PIM1 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.